摘要
目的:研究不同强度阿托伐他汀对急性冠脉综合征(Acute coronary syndrome,ACS)患者高敏C反应蛋白(Highsensitivity C reactive protein,hs-CRP)的影响。方法:将2012年1月-2014年12月在遂宁市中心医院就诊的100例急性冠脉综合征患者和50例健康体检者分为阿托伐他汀中等强度组(20mg·d-1)、阿托伐他汀高强度组(40mg·d-1)和对照组,每组各50例,分别测定治疗前及治疗7天后急性冠脉综合征患者hs-CRP的浓度并进行比较分析。结果:治疗前ACS患者的hs-CRP的浓度显著高于对照组(P<0.05)。治疗7天后中等强度组和高强度组的hs-CRP较治疗前显著降低(P<0.05),并且高强度组较中等强度组的降低幅度更大(P<0.05)。但是两组治疗7天后的hs-CRP仍高于对照组(P<0.05)。结论:炎症反应贯穿ACS发展过程,阿托伐他汀明显降低ACS患者hs-CRP浓度,高强度阿托伐他汀更能显著抑制ACS的炎症反应。
Objective：To investigate the effect of atorvastatin with different doses on high-sensitivity C reactive protein（hsCRP）＇s concentration in patients with acute coronary syndrome（ACS）.Methods：One hundred patients with ACS and 50 health peoples in Suining Central Hospital from January 2012 to December 2014 were randomly divided into medium dose group（20mg·d-1atorvastatin）,high dose group（40mg·d-1 atorvastatin）and control group.Concentration of plasma hs-CRP was detected and compared before treatment and after 7days treatment.Results：Concentration of plasma hs-CRP in ACS patients before treatment was notably higher than control group（P〈0.05）.After 7days treatment,concentrations of plasma hs-CRP was decreased significantly in both medium dose group and high dose group（P〈0.05）,and concentrations of plasma hs-CRP in high dose group decreased more significantly than medium dose group（P〈0.05）.But concentrations of plasma hs-CRP in both medium dose group and high dose group after 7days treatment were still higher than control group（P〈0.05）.Conclusions：The inflammatory reaction plays critical role in ACS.Atorvastatin can significantly decrease the concentration of plasma hs-CRP in patients with ACS.High dose atorvastatin can more notably suppress inflammatory reaction in ACS.
出处
《四川生理科学杂志》
2015年第3期118-120,共3页
Sichuan Journal of Physiological Sciences
关键词
冠状动脉疾病
炎症
C反应蛋白
阿托伐他汀
Coronary artery disease
Inflammation
C reactive protein
Atorvastatin
